---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-21-000041"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2021-08-04T23:59:59+00:00"
generated_at: "2026-06-29T22:45:50.702194+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation

## Summary
- Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.
- Gross margin 96% aided by $14.7M one-time royalty reversal from Bio-Rad settlement.
- Launched Chromium X platform and began shipping Visium Spatial Gene Expression for FFPE.
- Global settlement with Bio-Rad resolves all outstanding litigation; cross-license agreement.
- Maintains FY2021 revenue guidance $480M-$500M, representing 61%-67% growth.

## SEC filing metadata
- accession: 0001770787-21-000041
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2021-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/0001770787-21-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/txg-20210804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-21-000041
- JSON: https://secwatch.observer/filing/0001770787-21-000041.json
- Plain text: https://secwatch.observer/filing/0001770787-21-000041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.